AnaptysBio (NASDAQ:ANAB – Get Free Report) released its earnings results on Monday. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82), Yahoo Finance reports. The company had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%.
AnaptysBio Trading Down 0.9 %
Shares of ANAB stock opened at $32.08 on Wednesday. The firm’s fifty day moving average price is $28.03 and its two-hundred day moving average price is $25.11. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $38.85. The firm has a market capitalization of $876.39 million, a P/E ratio of -5.22 and a beta of -0.25.
Insider Transactions at AnaptysBio
In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the completion of the transaction, the insider now directly owns 11,618 shares in the company, valued at $406,630. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the sale, the insider now directly owns 11,618 shares of the company’s stock, valued at approximately $406,630. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Hollings Renton sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $30.64, for a total value of $306,400.00. Following the transaction, the director now directly owns 1,950 shares in the company, valued at approximately $59,748. The disclosure for this sale can be found here. Insiders sold a total of 16,900 shares of company stock worth $484,824 in the last three months. Insiders own 33.70% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on AnaptysBio
About AnaptysBio
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Further Reading
- Five stocks we like better than AnaptysBio
- What Investors Need to Know About Upcoming IPOs
- Lumen’s Q2: Can AI Revenue Outshine a Mountain of Debt?
- Stock Dividend Cuts Happen Are You Ready?
- Carry Trade Ending: Recent Market Turbulence and Future Risks
- Canada Bond Market Holiday: How to Invest and Trade
- Stocks Slide: Trillions Lost, More Downside Ahead?
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.